Brainstorm Cell Therapeutics Inc. (BCLI) Financial Ratios
24 years of historical data (2001–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
N/A
—
5yr avg: 5.92
30Y Low0.1·High158.7
ROE
↓
N/A
—
5yr avg: -220.1%
30Y Low-297%·High-41%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BCLI Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Brainstorm Cell Therapeutics Inc. trades at 0.3x earnings, 69% below its 5-year average of 1.0x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.3x, the stock trades at a discount of 99%.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $7M | $12M | $16M | $60M | $145M | $153M | $109M | $74M | $74M | $47M | $53M |
| Enterprise Value | $8M | $13M | $16M | $63M | $132M | $123M | $111M | $73M | $72M | $47M | $53M |
| P/E Ratio → | 0.32 | 1.04 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 8.27 | 14.20 | — | — | — | — | — | — | — | — | — |
| P/B Ratio | — | — | — | — | 7.52 | 4.32 | — | 14.74 | 12.65 | 4.79 | 3.75 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
BCLI EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 14.82 | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
BCLI Profitability
Margins and return-on-capital ratios measuring operating efficiency
Brainstorm Cell Therapeutics Inc. earns an operating margin of -1377.3%.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | — | — | — | — | 200.0% | — | — | — | — |
| Operating Margin | -1377.3% | -1377.3% | — | — | — | — | 6284.4% | — | — | — | — |
| Net Profit Margin | 1369.0% | 1369.0% | — | — | — | — | 6353.3% | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | -297.4% | -89.2% | -273.7% | — | -256.0% | -62.8% | -41.5% | -81.6% |
| ROA | 384.9% | 384.9% | -271.6% | -128.7% | -60.7% | -110.1% | -261.8% | -123.2% | -44.6% | -35.8% | -62.9% |
| ROIC | — | — | — | -634.2% | -353.4% | — | — | -282.4% | -58.8% | -33.1% | -79.4% |
| ROCE | — | — | — | -219.6% | -77.9% | -219.2% | — | -258.1% | -63.4% | -42.3% | -81.6% |
BCLI Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $533000 ($720000 total debt minus $187000 cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 0.26 | 0.20 | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | -0.71 | -0.86 | — | -0.19 | -0.42 | -0.06 | -0.03 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -151.86 | -151.86 | — | — | — | — | — | — | — | — | — |
BCLI Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.04x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 0.35x to 0.04x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.04 | 0.04 | 0.24 | 0.35 | 3.69 | 3.85 | 0.19 | 1.65 | 1.74 | 12.09 | 5.69 |
| Quick Ratio | 0.04 | 0.04 | 0.24 | 0.35 | 3.69 | 3.85 | 0.19 | 1.65 | 1.74 | 12.09 | 5.69 |
| Cash Ratio | 0.02 | 0.02 | 0.17 | 0.34 | 3.50 | 3.73 | 0.03 | 1.14 | 1.40 | 11.56 | 5.40 |
| Asset Turnover | — | 0.46 | — | — | — | — | -0.06 | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 27.08 | — | — | — | — | — | — | — | — | — |
BCLI Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Brainstorm Cell Therapeutics Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 100.0% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 100.0% | 96.5% | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $5M | $4M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $1M |
Peer Comparison
Compare BCLI with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BCLIYou | $7M | 0.3 | — | — | 100.0% | -1377.3% | — | — | — |
 CLLS | $280M | -9.4 | — | 14.4 | 77.9% | -143.5% | -34.1% | -79.6% | — |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 SNGX | $3M | -0.1 | — | — | — | — | -249.0% | — | — |
 BIIB | $28B | 21.7 | 11.4 | 13.8 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
 IONS | $13B | -31.9 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 PRTA | $567M | -2.3 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
 ARVN | $652M | -8.0 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
 ALNY | $39B | 127.0 | 70.2 | 84.8 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 23 years · Updated daily
See BCLI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BCLI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BCLI vs CLLS
Side-by-side business, growth, and profitability comparison vs Cellectis S.A..
Start ComparisonBCLI — Frequently Asked Questions
Quick answers to the most common questions about buying BCLI stock.
What is Brainstorm Cell Therapeutics Inc.'s P/E ratio?
Brainstorm Cell Therapeutics Inc.'s current P/E ratio is 0.3x. The historical average is 1.0x.
Is BCLI stock overvalued?
Based on historical data, Brainstorm Cell Therapeutics Inc. is trading at a P/E of 0.3x. Compare with industry peers and growth rates for a complete picture.
What are Brainstorm Cell Therapeutics Inc.'s profit margins?
Brainstorm Cell Therapeutics Inc. has 100.0% gross margin and -1377.3% operating margin.